Can a lower dose of avastin save sight in preemies?

NCT ID NCT04634578

Ongoing Disease control Sponsor: Jaeb Center for Health Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether lower doses of the drug bevacizumab (Avastin) can effectively treat a severe form of retinopathy of prematurity (ROP) in premature infants. The trial includes 77 babies with type 1 ROP in zone I, the most dangerous type. Each infant receives a single injection of either 0.063 mg or 0.25 mg of bevacizumab into the affected eye(s). The main goal is to see if the disease improves within 4 weeks without needing additional treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin) injection into the eye
What this could lead to: If successful, this could show that lower doses of bevacizumab are effective for severe ROP, potentially reducing side effects while still saving sight.
What could go wrong: This is a small Phase 2 trial with only 77 infants, so results may not apply to all cases. Lower doses might not work as well as standard doses, and recurrence of ROP is possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinopathy of prematurity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINOPATHY OF PREMATURITY

Contacts and locations

Locations

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611, United States
Arkansas Childrens Hospital/ University of Arkansas Medical Sciences

Little Rock, Arkansas, 72202, United States
Boston Children's Hospital

Boston, Massachusetts, 02215, United States
Casey Eye Institute

Portland, Oregon, 97239, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Cincinnati Children's Hospital

Cincinnati, Ohio, 45229, United States
Duke University Eye Center

Durham, North Carolina, 27710, United States
Greater Baltimore Medical Center

Baltimore, Maryland, 21204-5809, United States
IWK Health Centre

Halifax, Nova Scotia, B3K 6R8, Canada
Indiana University School of Medicine

Indianapolis, Indiana, 46202, United States
Jules Stein Eye Institute at the University of California, Los Angeles

Los Angeles, California, 90095, United States
New York Presbyterian David H Koch Center

New York, New York, 10065, United States
Pediatric Ophthalmology Associates, Inc.

Columbus, Ohio, 43205, United States
Riley Hospital for Children

Indianapolis, Indiana, 46202, United States
Storm Eye Institute

Mt. Pleasant, South Carolina, 29464, United States
Texas Children's Hospital - Dept. Of Ophthalmology

Houston, Texas, 77030, United States
The Emory Eye Center

Atlanta, Georgia, 30322, United States
U of Illinois at Chicago Eye and Ear Infirmary

Chicago, Illinois, 60612, United States
UK Ophthalmology and Visual Sciences, The Eye Clinic

Lexington, Kentucky, 40508, United States
UPMC Children's Eye Center of Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, 15224, United States
Univ of California, Irvine- Gavin Herbert Eye Institute

Irvine, California, 92697, United States
University of California San Francisco Department of Ophthalmology

San Francisco, California, 94143, United States
University of California, Davis

Sacramento, California, 95817, United States
University of Chicago

Hyde Park, Illinois, 60637, United States
University of Utah Moran Eye Center

Salt Lake City, Utah, 84132, United States
Virginia Pediatric Eye Center

Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.